lacking for their characterization and follow up. We report an extensive cytokine screening performed in serum from 44 MMF patients compared both to sex and agematched healthy controls and to patients with various types of inflammatory neuromuscular diseases. Thirty cytokines were quantified using combination of LuminexR technology and ELISA. There was significant mean increase of serum levels of the monocyte-chemoattractant protein 1 (CCL2/MCP-1) in MMF patients compared to healthy subjects. MMF patients showed no elevation of other cytokines. This contrasted with inflammatory patients in whom CCL2/MCP-1 serum levels were unchanged, whereas several other inflammatory cytokines were elevated (IL1!, IL5
clinical manifestations of ASIA have been reported, biological markers are particularly lacking for their characterization and follow up. We report an extensive cytokine screening performed in serum from 44 MMF patients compared both to sex and agematched healthy controls and to patients with various types of inflammatory neuromuscular diseases. Thirty cytokines were quantified using combination of LuminexR technology and ELISA. There was significant mean increase of serum levels of the monocyte-chemoattractant protein 1 (CCL2/MCP-1) in MMF patients compared to healthy subjects. MMF patients showed no elevation of other cytokines. This contrasted with inflammatory patients in whom CCL2/MCP-1 serum levels were unchanged, whereas several other inflammatory cytokines were elevated (IL1!, IL5 and CCL3/MIP1"). These results suggest that CCL2 may represent a biological marker relevant to the pathophysiology of MMF rather than a non specific inflammary marker and that it should be checked in the other syndromes constitutive of ASIA. leading to virtual eradication of several infectious diseases. The extending scope of possible immunization strategies has promoted vaccine as a priviledged weapon against a variety of diseases. As a general rule, vaccine safety has been considered excellent in the overall population [1] but adverse reactions to vaccines were long suspected to occur in a very small minority of cases [2] . Their mechanism usually remains unclear. Vaccine adverse reactions could represent autoimmune phenomena similar to those following natural infections [3] . For example, autoimmune diseases [4] , attention has progressively focussed on possible implication of some adjuvants used to boost the immune response, including aluminium oxyhydroxide or alum [5, 6] and squalene [7, 8] . It is likely that a fine balance exists between the efficacy of vaccine adjuvants and their potential toxicity, and these may be one and the same effect [9] . Adjuvants may exert their immunostimulatory effect by many different actions, including: (a) protection of antigens resulting in prolonged delivery; (b) induction of prompt vaccine particle phagocytosis by dendritic cells and macrophages with up-regulation of their antigen-presenting function; (c) translocation of antigens to lymphoid organs where the primary activation of naïve T cells takes place; (d) amplification of the inflammatory reaction in the injection site and its draining lymph nodes through interaction with pattern recognition receptors and release of inflammatory cytokines; and (e) priming of B cells in spleen [9, 10, 11] .
Vaccine adverse effects include specific autoimmune diseases that are easily identified using well established criteria but also ill-defined conditions usually manifesting by symptoms such as myalgia, arthralgia, chronic fatigue and the appearance of autoantibodies [12] . Yehuda Shoenfeld had the great merit to tentatively delineate a syndrome entitled "Autoimmune (Autoinflammatory) syndrome Induced by Adjuvants" (ASIA) in order to alert physicians when the above-mentioned symptoms do appear following vaccination [13] . As noted previously by others [14] he pointed out remarkable similarities between different syndromes linked to vaccine adjuvants, including the one associated with macrophagic myofasciitis, a lesion assessing longterm persistence of vaccine-derived alum into macrophages at site of previous immunization [15] and the so-called Gulf war syndrome that developed in soldiers exposed to intense immunization protocols [16] with vaccines containing alum [17] and possibly squalene [7] . Yehuda Shoenfeld also noted similarities with siliconosis, a disease complex observed in patients with leaky breast silicone implants which was long attributed to deleterious adjuvanticity of silicone particles [18, 19] . He unified, under the heading of ASIA, the 3 syndromes with other post-vaccinal events, and proposed a set of major and minor diagnostic criteria as a guide for characterization and follow-up of these conditions [13] . These criteria still need validation but, notably, ASIA grab the attention of the international medical community rapidly after its delineation [20, 21, 22] pointing to a need in the field [15, 23] . In addition to clinical manifestations, it could prove very useful to identify biomarkers that may either help unify the ASIA concept in the future or, alternatively, point out subtle differences among its constitutive syndromes. In the present study we performed extensive cytokine screening in serum of patients with alum-related MMF. This allowed us to detect selective increase of the monocyte chemotactic protein 1/ C-C motif ligand 2 (MCP-1/CCL2), pointing out this chemokine as a first candidate biomarker to be tested in other ASIA subsets. proposed for ASIA [13] were met, including (1) "exposure to adjuvant prior to clinical 7 manifestations" (i.e. aluminium oxyhydroxide), with a previously reported median time of 7 months (range 0.5-84) elapsed from last vaccine administration to initial systemic symptoms, and 11 months (range 0-72) for first myalgia [15] ; (2) "the appearance of typical clinical manifestations" including: myalgia; arthralgias; chronic disabling fatigue; urefreshing sleep or sleep disturbances; cognitive impairment and memory loss [27] ; and, less often, overt neurological manifestations associated with demyelination [28] ; and (3) "typical biopsy of involved organs" , i.e. MMF [24] . Notably, in contrast to the leaky silicone breast implant-associated ASIA, the criterion "removal of inciting agent induces improvement" could not be met in our patients subjected to multiple vaccine shots. A variable proportion of MMF patients also met minor criteria for ASIA, including (1) "the appearance of autoantibodies", (2) "other clinical manifestation" such as dyspnea, (3) "specific HLA", i.e. HLADRB1; and (4) "evolvement of an autoimmune disease", i.e. mainly multiple sclerosis thyroiditis, and autoimmune myopathies [15] .
PATIENTS AND METHODS
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The cytokine study subjects and controls. Chemokine serum levels were 
RESULTS
Multiplex cytokine serum analysis showed significantly increased mean CCL2/MCP-1 levels in MMF patients with ASIA compared with healthy subjects (median = 57.7 vs. 37.9 pg/mL; mean = 64.5+/-32.9 vs. 38.2+/-11.5 pg/ml, p<0.0001) (Fig. 2) . Increase was unique to CCL2/MCP-1, as the other tested inflammatory cytokines, chemokines, and growth factors were either similar (IFN#, TNF", IL5, IL6, IL7, IL13, G-CSF, PDGFbb, VEGF, CCL3, CCL4, CCL5, CCL7, CCL11, CXCL8, CXCL1, CXCL10, and CX3CL1, p= NS), or even decreased (IL1!, IL1ra, IL4, IL10, IL12p70, IL17, FGFb, all p <0.05) in MMF patients compared to healthy controls. The CCL2/MCP1 variation could not be attributed to smoking habits (p=NS for all tested molecules). Inflammatory controls showed no difference for serum CCL2/MCP-1 levels (median 47.9; mean 52.8+/-25.9pg/mL) compared with both MMF and healthy control patients (p=NS). In contrast, inflammatory controls had significantly increased mean levels of several inflammatory cytokines compared to MMF patients (IL1b, IL5 and CCL3/MIP1a, all p< 0.04), and to healthy controls (CCL3/MIP1a, p<0.02). Similarly to MMF patients, inflammatory controls had decreased mean IL17 and FGFb levels compared to healthy controls (Fig. 3) .
DISCUSSION
The salient finding of this crossectional screening of 30 cytokines was the selective increase of CCL2/MCP-1 serum levels in MMF patients with ASIA compared to ageand sex-matched healthy individuals. Notably, similar increase of circulating CCL2/MCP1 levels was not detected in inflammatory controls, whereas other inflammatory molecules, including IL1!, IL5 and CCL3/MIP1a levels, were higher in this group. Furthermore, MMF patients had lower mean levels of IL1b and IL1ra compared to healthy controls, pointing to CCL2/MCP-1 as a marker relevant to the pathophysiology of MMF rather than a non-specific inflammatory marker. They also had lower mean levels of IL 4 and IL10 of unknown significance.
MMF assesses long-term persistence of alum crystal agglomerates within macrophages at the site of previous i.m. immunization [5] . Such a biopersistence of alum is detected in the deltoid muscle a small minority of alum-adjuvanted vaccine receivers, strongly suggesting the influence of genetic factors, as previously documented in rats in which the lesion size conspicuously varies according to the genetic background [29] , The rarity of ASIA in the general population may also reflect specific gene-environment interactions [13] . Adjuvant effects of alum remain incompletely understood [9] . In vitro studies have shown that alum acts mainly on macrophages and monocytes, skewing monocyte differentiation toward inflammatory DCs (iDCs) [30] . Whereas classical iDCs do not secrete CCL2, iDCs differentiating in the presence of alum produce high amounts of CCL2 from day 4 onward, and this does not appear to simply reflect particle uptake [30] . Unlike LPS which induces a wide proinflammatory response, alum does not upregulate other cytokines, if one excepts CCL4, and, therefore, likely acts through a mechanism distinct from that of danger signals [30] . In addition to monocyte/macrophage lineage cells, CCL2 is produced by many cell types, including for example endothelial, fibroblasts, smooth muscle, astrocytic, and microglial cells [31] . CCL2 acts through its receptor CCR2, which expression is restricted to certain type of cells, such as monocytes, T and NK cells [31] .
CCL2 is the main chemokine responsible for recruiting inflammatory monocytes to tissues, as previously documented in both injured muscle [32] and brain [33, 34] .
Certain individuals are genetically programmed to produce copious amounts of MCP-1, and these individuals were reported to be at higher risk of developing severe forms of diseases implicating macrophages in their pathophysiology, including atherosclerosis [35] , tuberculosis [36] , sarcoidosis [37] , pneumoconiosis [38] , lupus erythematosus [39, 40] , and HIV-associated dementia [41] . In light of these reports, selective increase of CCL2/MCP1 serum levels in MMF patients suggests that functional polymorphisms in the promoter of the MCP-1 gene should be screened as possible genetic susceptibility factors to develop the condition after alum administration. For example, CCL2 expression is associated with the development of polarized Th2 immune responses [42] , and both CCL2/MCP1 and Th2 cells increase in blood during normal ageing [43] . Th2 cytokines may disturb the xeno/autophagy process [44] used by macrophages to handle both infectious and non-biodegradable particles [45] . Here again, genetic susceptibility factors further impacting the xeno/autophagic machinery should be searched in MMF patients in light of recent reports linking polymorphisms in certain genes with inability of cells to clear out infectious particles in Crohn disease [46] , a chronic inflammatory gastrointestinal disease in which aluminium may also play a role [47] .
In a prelimary series of mouse experiments, we observed that nanomaterials injected into muscle, including latex beads and fluorescent alum surrogates, are quickly captured by monocyte lineage cells and disseminate in the body in a CCL2-dependent manner, as demonstrated by gain and loss of CCL2 function experiments [48] .
Particles are transported by MO-lineage cells to the draining lymph nodes, then reach blood and spleen, and, after a long delay and at a much lower rate, gain the brain where they accumulate and persist mainly within microglial cells. Alum adjuvant injected twice into mice at human equivalent doses to mimick vaccine exposure of individuals with Gulf war syndrome results in conspicuous neurotoxic effects, as assessed by behavioural and motor testings, and by neuropathologic evidence of microglial activation and motoneuronal death [17] . CCL2 is constitutively present in the central nervous system where it acts both as chemoattractant and neuromodulator [49] .
CCL2 is an important mediator of the neuroinflammatory responses in chronic neurologic disorders such as multiple sclerosis [50] , Alzheimer!s disease [51] and human HIV-1-associated dementia [52] . Several CCL2 neuromodulatory effects have been documented. For example CCL2 protects against toxicity of trace metals such as methylmercury at low dose, protection ceasing and marked toxicity ensuing when exposure becomes chronic or when too much CCL2 is released by glial cells [53] .
Consistently, chronic CCL2 overexpression is associated with delayed encephalopathy and impaired microglial function [54] . Moreover, CCL2 is crucially involved in the development of pain [55, 56, 57] , CCL2-induced central sensitization to pain being mediated by increasing the activity of NMDA receptors in dorsal horn neurons [58] . In keeping with these effects, circulating CCL2/MCP1 elevation was previously reported in patients with fibromyalgia, in combination with IL8 elevation [59] , which was not detected in the present study, and with mild cognitive impairment [60] . Consistently,
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MMF patients have chronic myalgias combined with fatigue and mild cognitive impairment of the multi-domain type [26] . We suggest that circulating MCP-1 levels should be tested as a possible biomarker in the other ASIA subsets. 
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